Stock Scorecard



Stock Summary for Citius Pharmaceuticals Inc (CTXR) - $0.54 as of 10/29/2026 6:17:42 PM EST

Total Score

15 out of 30

Safety Score

25 out of 100

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for CTXR

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CTXR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CTXR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CTXR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CTXR (25 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CTXR

Citius Oncology LYMPHIR wholesaler units rise 120% in Q4 2026 10/26/2026 6:11:00 PM
Citius Pharmaceuticals, Inc. Estimates – NASDAQ:CTXR 10/23/2026 4:09:00 PM
Citius Pharmaceuticals Inc (CTXR-Q) Stock Price and News 10/16/2026 8:12:00 PM
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences 10/13/2026 6:40:00 AM
Citius Pharmaceuticals stock carries LYMPHIR into fiscal Q3 10/6/2026 11:32:00 AM
Citius Pharmaceuticals stock reports USD 7.1 million LYMPHIR revenue 10/1/2026 5:54:00 AM
Citius Pharmaceuticals stock trades quietly as investors await next catalysts 9/18/2026 6:24:00 AM
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences 9/3/2026 6:54:00 AM
Citius Pharma CEO to speak at two New York conferences 9/2/2026 6:24:00 AM
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard 8/21/2026 8:42:00 PM

Financial Details for CTXR

Company Overview

Ticker CTXR
Company Name Citius Pharmaceuticals Inc
Country USA
Description Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. The company is headquartered in Cranford, New Jersey.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 0.54
Price 4 Years Ago 19.75
Last Day Price Updated 10/29/2026 6:17:42 PM EST
Last Day Volume 203,194
Average Daily Volume 242,519
52-Week High 1.63
52-Week Low 0.37
Last Price to 52 Week Low 45.95%

Valuation Measures

Trailing PE N/A
Industry PE 35.94
Sector PE 57.70
5-Year Average PE -2.21
Free Cash Flow Ratio 0.87
Industry Free Cash Flow Ratio 37.15
Sector Free Cash Flow Ratio 39.66
Current Ratio Most Recent Quarter 0.84
Total Cash Per Share 0.62
Book Value Per Share Most Recent Quarter 2.43
Price to Book Ratio 0.19
Industry Price to Book Ratio 11.97
Sector Price to Book Ratio 37.05
Price to Sales Ratio Twelve Trailing Months 1.94
Industry Price to Sales Ratio Twelve Trailing Months 11.49
Sector Price to Sales Ratio Twelve Trailing Months 20.95
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 27,452,600
Market Capitalization 14,824,404
Institutional Ownership 4.95%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 4.36%
Reported EPS 12 Trailing Months -1.75
Reported EPS Past Year -1.67
Reported EPS Prior Year -3.48
Net Income Twelve Trailing Months -46,274,055
Net Income Past Year -37,433,911
Net Income Prior Year -39,138,839
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 100.57%
Operating Margin Twelve Trailing Months -670.00%

Balance Sheet

Total Cash Most Recent Quarter 17,007,523
Total Cash Past Year 4,252,290
Total Cash Prior Year 3,251,880
Net Cash Position Most Recent Quarter 10,597,362
Net Cash Position Past Year 3,914,737
Long Term Debt Past Year 337,553
Long Term Debt Prior Year 337,553
Total Debt Most Recent Quarter 6,410,161
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 0.91
Total Stockholder Equity Past Year 67,550,178
Total Stockholder Equity Prior Year 70,077,450
Total Stockholder Equity Most Recent Quarter 66,613,132

Free Cash Flow

Free Cash Flow Twelve Trailing Months -34,867,207
Free Cash Flow Per Share Twelve Trailing Months -1.27
Free Cash Flow Past Year -26,552,738
Free Cash Flow Prior Year -28,201,375

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.44
20-Day Bollinger Middle Band 0.57
20-Day Bollinger Upper Band 0.70
Beta 1.00
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 10/28/2026 9:45:58 PM EST